Current stock page

Catalysts

TXG Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - Healthcare Information ServicesScore data as of Sep 4, 2026

TXG

Catalysts
10x Genomics, Inc.
Healthcare· Medical - Healthcare Information Services
AIQ Score
NeutralAIQ Edge 5/10
Low Priority
In Line With Peers
Score data as of Sep 4, 2026
Last price
$62.65
-$0.57 (-0.90%)
Latest market quote
Momentum67
Value34
Quality59
Risk Resilience38
Sentiment68
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 5, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 50/100

Momentum 67/100 and sentiment 68/100 before the next covered event.

Recent coverage
5 articles

Updated Sep 5, 2026 · Sentiment 39.50%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 67/100AIQ Edge 5/10 In Line With Peers
Beat rate
75%
6 of 8 reported periods
Average surprise
+12.4%
Across covered historical reports
Latest result
+42.4%
Aug 6, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 6, 2026-$0.24-$0.14+42.4%$146.67M$151.04M
May 7, 2026-$0.29-$0.10+65.5%$146.41M$150.84M
Feb 12, 2026-$0.19-$0.13+31.6%$159.65M$166.03M
Nov 6, 2025-$0.07-$0.22-214.3%$142.5M$149M
Aug 7, 2025-$0.35$0.28+180.0%$139.51M$172.91M
May 8, 2025-$0.45-$0.36+20.0%$145.27M$154.88M
Feb 12, 2025-$0.29-$0.40-37.9%$164.98M$165.02M
Oct 29, 2024-$0.34-$0.30+11.8%$153.32M$151.65M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Hold
6
Buy
10
Hold
12-month analyst target
$43.73
-30.20% versus current price
Based on 7 analyst observations. Targets are estimates, not predictions.
Low target
$22.00
-64.88% vs latest price
Average target
$43.73
-30.20% vs latest price
High target
$65.00
+3.75% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 5, 2026

Next known earnings or reporting date.

EPS estimate-$0.27

Current analyst expectation for the upcoming report.

Revenue estimate$147.28M

Current analyst expectation for the upcoming report.

Sentiment score68

News pressure around the setup.

Momentum score67

Where event reaction would show up first.

AIQ score50/100

Composite decision read before event confirmation.

Analyst context

Consensus
Hold
Analysts
7
Average target
$43.73
Target upside
-30.20%
Target range
$22.00 - $65.00
90-day revisions
16

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
5
Neutral
0
Negative
0
gurufocus.com · Sep 1, 2026

TXG Initiated Coverage by RBC Capital -- Rating Set to Sector Perform

10x Genomics (TXG) Analyst Rating Update On September 1, 2026, RBC Capital initiated coverage of 10x Genomics (TXG) with a rating of Sector Perform. The curr

gurufocus.com · Aug 29, 2026

10x Genomics Inc (TXG) Shares Fall 5.1% -- GF Value Says Still Overvalued

On August 28, 2026, 10x Genomics Inc (TXG) shares fell 5.1% to a current price of $61.55. The stock has experienced significant volatility, trading between $11.

gurufocus.com · Aug 28, 2026

TXG Looks 235.1% Overvalued on GF Value™

On August 28, 2026, 10x Genomics Inc (NASDAQ: TXG) secured a notable legal win as a Delaware jury ruled that Parse Biosciences, a Qiagen subsidiary, willfully i

gurufocus.com · Aug 26, 2026

10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Shares

Director Shehnaaz Suliman sold 2,207 shares of 10x Genomics Inc (TXG) on 2026-08-24, according to a recent SEC Filing. Following the transaction, the insider no

finance.yahoo.com · Aug 18, 2026

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

On August 6, 10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara. Strip that out and revenue grew just 3% year-over-year to $149.4 million, a modest number next to the real headline of the quarter: a brand-new instrument platform called Atera, where booked orders have exceeded […]

Open full news and sentiment

TXG Catalysts FAQ

What are the next catalysts for TXG stock?

TXG's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TXG stock?

Upcoming events that could move TXG include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TXG's next earnings report affect the stock?

TXG's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TXG stock higher?

TXG could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TXG stock?

TXG could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.